GENE ONLINE|News &
FDA Accepts Novo Nordisk NDA for 25 mg Oral Wegovy
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for a 25 mg oral formulation of Wegovy (semaglutide). This submission marks a key step in potentially expanding the availability of Wegovy to patients through an oral medication. The NDA specifically pertains to a 25 mg tablet form of semaglutide, the active ingredient in Wegovy. The acceptance of the application by the FDA signifies that the agency has deemed the submission complete enough to begin its review process. Wegovy is currently available as an injectable medication.
Newsflash | Powered by GeneOnline AI
Date: May 5, 2025
Author
LATEST
The Targeted Strike – ADCs and Bispecifics Delivering Precision Payloads in Modern Oncology
2026-04-15
Researchers Develop New Method to Detect Extraterrestrial Life by Analyzing Patterns Across Planetary Populations
2026-04-15
Early Patient Involvement in Drug Development Linked to Reduced Costs and Faster Timelines
2026-04-15
Policy, Pricing, and Power: Why Europe’s Biotech Future Depends on Openness, Not Overregulation
2026-04-14
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
